Creating a vaccine to prevent Chlamydia infections
Development of a recombinant protein vaccine for Chlamydia trachomatis
['FUNDING_U01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11061077
This study is working on a new vaccine to help protect against Chlamydia, a common infection that can affect reproductive health, by using a special protein from the bacteria to boost your immune system, and it’s designed to be given through the nose for better protection.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-11061077 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a vaccine against Chlamydia trachomatis, a bacterium that causes significant reproductive health issues. The approach involves using a specific protein from the bacterium, combined with powerful adjuvants, to stimulate the immune system effectively. By targeting both T cells and B cells, the vaccine aims to provide robust protection against the infection. The research includes innovative methods of delivering the vaccine intranasally to enhance immune response in the female genital tract.
Who could benefit from this research
Good fit: Ideal candidates for this research are sexually active women who are at risk of Chlamydia infections.
Not a fit: Patients who are not sexually active or those who have already been vaccinated against Chlamydia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of Chlamydia infections and their associated reproductive complications.
How similar studies have performed: Previous research has shown promise in developing vaccines for other sexually transmitted infections, indicating potential success for this novel approach.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DARVILLE, TONI — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: DARVILLE, TONI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.